Hyperglycemic crises in adults with diabetes: a consensus report

1.

Umpierrez G, Korytkowski M (2016) Diabetic emergencies — ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol 12:222–232. https://doi.org/10.1038/nrendo.2016.15CrossRefPubMed

2.

Dhatariya KK, Joint British Diabetes Societies for Inpatient Care (2022) The management of diabetic ketoacidosis in adults—an updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med 39:e14788 https://doi.org/10.1111/dme.14788

3.

Dhatariya KK, Glaser NS, Codner E, Umpierrez GE (2020) Diabetic ketoacidosis. Nat Rev Dis Primers 6:40. https://doi.org/10.1038/s41572-020-0165-1CrossRefPubMed

4.

Zhong VW, Juhaeri J, Mayer-Davis EJ (2018) Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998–2013: a retrospective cohort study. Diabetes Care 41:1870–1877. https://doi.org/10.2337/dc17-1583CrossRefPubMed

5.

McCoy RG, Herrin J, Galindo RJ et al (2023) Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011–2020. Diabetes Care 46:e69–e71. https://doi.org/10.2337/dc22-1673

6.

Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A (2018) Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality — United States, 2000–2014. MMWR Morb Mortal Wkly Rep 67:362–365. https://doi.org/10.15585/mmwr.mm6712a3CrossRefPubMedPubMedCentral

7.

Kitabchi AE, Umpierrez GE, Murphy MB et al (2001) Management of hyperglycemic crises in patients with diabetes. Diabetes Care 24:131–153. https://doi.org/10.2337/diacare.24.1.131CrossRefPubMed

8.

Misra S (2022) Rise in diabetic ketoacidosis during the COVID-19 pandemic: several questions remain. Lancet Diabetes Endocrinol 10:763–765. https://doi.org/10.1016/S2213-8587(22)00272-8CrossRefPubMedPubMedCentral

9.

Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB (2021) COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care 44:2645–2655. https://doi.org/10.2337/dc21-1318CrossRefPubMedPubMedCentral

10.

Pasquel FJ, Tsegka K, Wang H et al (2020) Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: a retrospective, hospital-based cohort study. Diabetes Care 43:349–357. https://doi.org/10.2337/dc19-1168CrossRefPubMed

11.

American Diabetes Association (2001) Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 24:1988–1996. https://doi.org/10.2337/diacare.24.11.1988CrossRef

12.

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32:1335–1343. https://doi.org/10.2337/dc09-9032CrossRefPubMedPubMedCentral

13.

Benoit SR, Hora I, Pasquel FJ, Gregg EW, Albright AL, Imperatore G. Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006–2015. Diabetes Care 2020;43:1057–1064 https://doi.org/10.2337/dc19-2449

14.

Vellanki P, Umpierrez GE (2017) Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr Pract 23:971–978. https://doi.org/10.4158/EP161679.RACrossRefPubMedPubMedCentral

15.

Lebovitz HE, Banerji MA (2018) Ketosis-prone diabetes (Flatbush diabetes): an emerging worldwide clinically important entity. Curr Diab Rep 18:120. https://doi.org/10.1007/s11892-018-1075-4CrossRefPubMedPubMedCentral

16.

McCoy RG, Galindo RJ, Swarna KS et al (2021) Sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises among adults with type 1 or type 2 diabetes in the US from 2014 to 2020. JAMA Netw Open 4:e2123471. https://doi.org/10.1001/jamanetworkopen.2021.23471CrossRefPubMedPubMedCentral

17.

Kikani N, Balasubramanyam A (2023) Remission in ketosis-prone diabetes. Endocrinol Metab Clin North Am 52:165–174. https://doi.org/10.1016/j.ecl.2022.06.005CrossRefPubMed

18.

Di Giovanni P, Meo F, Cedrone F et al (2020) Predictors and trend of ketoacidosis hospitalization rate in type 2 diabetes mellitus patients from 2006 to 2015 in Abruzzo region, Italy. Clin Ter 170:e53–e58. https://doi.org/10.7417/CT.2020.2189CrossRefPubMed

19.

Desai R, Singh S, Syed MH et al (2019) Temporal trends in the prevalence of diabetes decompensation (diabetic ketoacidosis and hyperosmolar hyperglycemic state) among adult patients hospitalized with diabetes mellitus: a nationwide analysis stratified by age, gender, and race. Cureus 11:e4353. https://doi.org/10.7759/cureus.4353CrossRefPubMedPubMedCentral

20.

Shaka H, El-Amir Z, Wani F et al (2022) Hospitalizations and inpatient mortality for hyperosmolar hyperglycemic state over a decade. Diabetes Res Clin Pract 185:109230. https://doi.org/10.1016/j.diabres.2022.109230CrossRefPubMed

21.

O’Reilly JE, Jeyam A, Caparrotta TM et al (2021) Rising rates and widening socioeconomic disparities in diabetic ketoacidosis in type 1 diabetes in Scotland: a nationwide retrospective cohort observational study. Diabetes Care 44:2010–2017. https://doi.org/10.2337/dc21-0689CrossRefPubMed

22.

Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA (2017) Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open 7:e016587. https://doi.org/10.1136/bmjopen-2017-016587CrossRefPubMed

23.

Mays JA, Jackson KL, Derby TA et al (2016) An evaluation of recurrent diabetic ketoacidosis, fragmentation of care, and mortality across Chicago, Illinois. Diabetes Care 39:1671–1676. https://doi.org/10.2337/dc16-0668CrossRefPubMed

24.

Dhatariya KK, Nunney I, Higgins K, Sampson MJ, Iceton G (2016) National survey of the management of diabetic ketoacidosis (DKA) in the UK in 2014. Diabet Med 33:252–260. https://doi.org/10.1111/dme.12875CrossRefPubMed

25.

Hurtado CR, Lemor A, Vallejo F et al (2019) Causes and predictors for 30-day re-admissions in adult patients with diabetic ketoacidosis in the United States: a nationwide analysis, 2010–2014. Endocr Pract 25:242–253. https://doi.org/10.4158/EP-2018-0457CrossRefPubMed

26.

McCoy RG, Herrin J, Lipska KJ, Shah ND (2018) Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. J Diabetes Complications 32:693–701. https://doi.org/10.1016/j.jdiacomp.2018.04.007

27.

Shaka H, Aguilera M, Aucar M et al (2021) Rate and predictors of 30-day readmission following diabetic ketoacidosis in type 1 diabetes mellitus: a US analysis. J Clin Endocrinol Metab 106:2592–2599. https://doi.org/10.1210/clinem/dgab372CrossRefPubMed

28.

Dhatariya KK, Skedgel C, Fordham R (2017) The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabet Med 34:1361–1366. https://doi.org/10.1111/dme.13427CrossRefPubMed

29.

Desai D, Mehta D, Mathias P, Menon G, Schubart UK (2018) Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. Diabetes Care 41:1631–1638. https://doi.org/10.2337/dc17-1379

30.

Fernando SM, Bagshaw SM, Rochwerg B et al (2019) Comparison of outcomes and costs between adult diabetic ketoacidosis patients admitted to the ICU and step-down unit. J Crit Care 50:257–261. https://doi.org/10.1016/j.jcrc.2018.12.014CrossRefPubMed

31.

Lyerla R, Johnson-Rabbett B, Shakally A, Magar R, Alameddine H, Fish L (2021) Recurrent DKA results in high societal costs - a retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol 7:13. https://doi.org/10.1186/s40842-021-00127-6CrossRefPubMedPubMedCentral

32.

Shaka H, Wani F, El-Amir Z et al (2021) Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: a review and a propensity-matched nationwide analysis. J Investig Med 69:1196–1200. https://doi.org/10.1136/jim-2021-001901CrossRefPubMed

33.

Gaffney A, Christopher A, Katz A et al (2019) The incidence of diabetic ketoacidosis during “emerging adulthood” in the USA and Canada: a population-based study. J Gen Intern Med 34:1244–1250. https://doi.org/10.1007/s11606-019-05006-6CrossRefPubMedPubMedCentral

34.

McCoy RG, Herrin J, Galindo RJ et al (2023) All-cause mortality after hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011-2020. Diabetes Res Clin Pract 197:110263. https://doi.org/10.1016/j.diabres.2023.110263

35.

Nishikawa T, Kinoshita H, Ono K et al (2021) Clinical profiles of hyperglycemic crises: a single-center retrospective study from Japan. J Diabetes Investig 12:1359–1366. https://doi.org/10.1111/jdi.13475CrossRefPubMedPubMedCentral

36.

Sato Y, Morita K, Okada A, Matsui H, Fushimi K, Yasunaga H (2021) Factors affecting in-hospital mortality of diabetic ketoacidosis patients: a retrospective cohort study. Diabetes Res Clin Pract 171:108588. https://doi.org/10.1016/j.diabres.2020.108588CrossRefPubMed

37.

Ibrahim A, Bayramoglu B, Hokenek NM, Tekyol D (2021) Lactate clearance during the first 2 hours after hospital admission: a useful biomarker for predicting 30-day mortality in patients with diabetic ketoacidosis. Int J Clin Pract 75:e14204. https://doi.org/10.1111/ijcp.14204CrossRefPubMed

38.

Ahuja W, Kumar N, Kumar S, Rizwan A (2019) Precipitating risk factors, clinical presentation, and outcome of diabetic ketoacidosis in patients with type 1 diabetes. Cureus 11:e4789. https://doi.org/10.7759/cureus.4789CrossRefPubMedPubMedCentral

39.

Chung ST, Perue GG, Johnson A et al (2006) Predictors of hyperglycaemic crises and their associated mortality in Jamaica. Diabetes Res Clin Pract 73:184–190. https://doi.org/10.1016/j.diabres.2006.01.004CrossRefPubMed

40.

Nkpozi MO, Akhidue K, Unachukwu CN, Chinenye S, Chappjumbo AU (2018) Hyperglycaemic emergencies in a tertiary health facility in south-eastern Nigeria. West Afr J Med 35:137–143PubMed

41.

Shand JAD, Morrow P, Braatvedt G (2022) Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol 59:1485–1492. https://doi.org/10.1007/s00592-022-01953-5CrossRefPubMed

42.

Gibb FW, Teoh WL, Graham J, Lockman KA (2016) Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia 59:2082–2087. https://doi.org/10.1007/s00125-016-4034-0CrossRefPubMedPubMedCentral

43.

Fadini GP, de Kreutzenberg SV, Rigato M et al (2011) Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. Diabetes Res Clin Pract 94:172–179. https://doi.org/10.1016/j.diabres.2011.06.018CrossRefPubMed

44.

Michaelis M, Shochat T, Shimon I, Akirov A (2021) Features and long-term outcomes of patients hospitalized for diabetic ketoacidosis. Diabetes Metab Res Rev 37:e3408. https://doi.org/10.1002/dmrr.3408CrossRefPubMed

45.

Otieno CF, Kayima JK, Omonge EO, Oyoo GO (2005) Diabetic ketoacidosis: risk factors, mechanisms and management strategies in sub-Saharan Africa: a review. East Afr Med J 82(Suppl.):S197–S203. https://doi.org/10.4314/eamj.v82i12.9382

46.

Davis TME, Davis W (2020) Incidence and associates of diabetic ketoacidosis in a community-based cohort: the Fremantle Diabetes Study Phase II. BMJ Open Diabetes Res Care 8:e000983. https://doi.org/10.1136/bmjdrc-2019-000983CrossRefPubMedPubMedCentral

47.

Dhatariya KK (2019) Defining and characterising diabetic ketoacidosis in adults. Diabetes Res Clin Pract 155:107797. https://doi.org/10.1016/j.diabres.2019.107797CrossRefPubMed

48.

Randall L, Begovic J, Hudson M et al (2011) Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors. Diabetes Care 34:1891–1896. https://doi.org/10.2337/dc11-0701CrossRefPubMedPubMedCentral

49.

Fayfman M, Pasquel FJ, Umpierrez GE (2017) Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am 101:587–606. https://doi.org/10.1016/j.mcna.2016.12.011CrossRefPubMedPubMedCentral

50.

Paulson WD, Gadallah MF (1993) Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci 306:295–300. https://doi.org/10.1097/00000441-199311000-00004CrossRefPubMed

51.

Del Degan S, Dubé F, Gagnon C, Boulet G (2019) Risk factors for recurrent diabetic ketoacidosis in adults with type 1 diabetes. Can J Diabetes 43:472-476.e1. https://doi.org/10.1016/j.jcjd.2019.01.008CrossRefPubMed

52.

Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW (1997) Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet 350:1505–1510. https://doi.org/10.1016/S0140-6736(97)06234-XCrossRefPubMed

53.

Delaney MF, Zisman A, Kettyle WM (2000) Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 29:683–705. https://doi.org/10.1016/S0889-8529(05)70159-6CrossRefPubMed

54.

Nyenwe EA, Loganathan RS, Blum S et al (2007) Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital. Endocr Pract 13:22–29. https://doi.org/10.4158/EP.13.1.22CrossRefPubMed

55.

Davis SN, Umpierrez GE (2007) Diabetic ketoacidosis in type 2 diabetes mellitus–pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab 3:730–731. https://doi.org/10.1038/ncpendmet0641CrossRefPubMed

56.

Nyenwe EA, Kitabchi AE (2011) Evidence-based management of hyperglycemic emergencies in diabetes mellitus. Diabetes Res Clin Pract 94:340–351. https://doi.org/10.1016/j.diabres.2011.09.012CrossRefPubMed

57.

Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE (1997) Hyperglycemic crises in urban blacks. Arch Intern Med 157:669–675. https://doi.org/10.1001/archinte.1997.00440270117011CrossRefPubMed

58.

Thomas M, Harjutsalo V, Feodoroff M, Forsblom C, Gordin D, Groop PH (2020) The long-term incidence of hospitalization for ketoacidosis in adults with established T1D—a prospective cohort study. J Clin Endocrinol Metab 105:231–241. https://doi.org/10.1210/clinem/dgz003CrossRef

59.

Kurani SS, Heien HC, Sangaralingham LR et al (2022) Association of area-level socioeconomic deprivation with hypoglycemic and hyperglycemic crises in US adults with diabetes. JAMA Netw Open 5:e2143597. https://doi.org/10.1001/jamanetworkopen.2021.43597CrossRefPubMedPubMedCentral

60.

Jiang DH, Herrin J, Van Houten HK, McCoy RG (2023) Evaluation of high-deductible health plans and acute glycemic complications among adults with diabetes. JAMA Netw Open 6:e2250602. https://doi.org/10.1001/jamanetworkopen.2022.50602CrossRefPubMedPubMedCentral

61.

Matthews S, Coates MM, Bukhman A et al (2022) Health system capacity to manage diabetic ketoacidosis in nine low-income and lower-middle income countries: a cross-sectional analysis of nationally representative survey data. EClinicalMedicine 55:101759. https://doi.org/10.1016/j.eclinm.2022.101759CrossRefPubMedPubMedCentral

62.

Reid LA, Mendoza JA, Merchant AT et al (2022) Household food insecurity is associated with diabetic ketoacidosis but not severe hypoglycemia or glycemic control in youth and young adults with youth-onset type 2 diabetes. Pediatr Diabetes 23:982–990. https://doi.org/10.1111/pedi.13386CrossRefPubMedPubMedCentral

63.

Goueslard K, Petit JM, Cottenet J, Chauvet-Gelinier JC, Jollant F, Quantin C (2018) Increased risk of rehospitalization for acute diabetes complications and suicide attempts in patients with type 1 diabetes and comorbid schizophrenia. Diabetes Care 41:2316–2321. https://doi.org/10.2337/dc18-0657CrossRefPubMed

64.

Price HC, Ismail K (2018) Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings. Diabet Med 35:997–1004. https://doi.org/10.1111/dme.13673CrossRefPubMed

65.

Brandstaetter E, Bartal C, Sagy I, Jotkowitz A, Barski L (2019) Recurrent diabetic ketoacidosis. Arch Endocrinol Metab 63:531–535PubMedPubMedCentral

66.

Trief PM, Xing D, Foster NC et al (2014) T1D Exchange clinic network. Depression in adults in the T1D exchange clinic registry. Diabetes Care 37:1563–1572. https://doi.org/10.2337/dc13-1867

67.

Petit JM, Goueslard K, Chauvet-Gelinier JC et al (2020) Association between hospital admission for ketoacidosis and subsequent suicide attempt in young adults with type 1 diabetes. Diabetologia 63:1745–1752. https://doi.org/10.1007/s00125-020-05206-4CrossRefPubMed

68.

Roberts SE, Goldacre MJ, Neil HAW (2004) Mortality in young people admitted to hospital for diabetes: database study. BMJ 328:741–742. https://doi.org/10.1136/bmj.328.7442.741CrossRefPubMedPubMedCentral

69.

Hermanns N, Caputo S, Dzida G, Khunti K, Meneghini LF, Snoek F (2013) Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes 7:1–10. https://doi.org/10.1016/j.pcd.2012.11.002CrossRefPubMed

70.

Fisher L, Polonsky W, Naranjo D, Strycker L, Hessler D A novel approach to understanding and assessing the emotional side of type 1 diabetes: the Type 1-Diabetes Distress Assessment System. Diabet Med 2024:e15282 https://doi.org/10.1111/dme.15282

71.

Jeyam A, Gibb FW, McKnight JA et al (2021) Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia 64:1320–1331. https://doi.org/10.1007/s00125-021-05413-7CrossRefPubMedPubMedCentral

72.

Biester T, Schwandt A, Heidtmann B et al (2021) Declining frequency of acute complications associated with tubeless insulin pump use: data from 2,911 patients in the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Technol Ther 23:527–536. https://doi.org/10.1089/dia.2020.0675CrossRefPubMedPubMedCentral

73.

Wersäll JH, Adolfsson P, Forsander G, Hanas R (2022) Insulin pump therapy is associated with higher rates of mild diabetic ketoacidosis compared to injection therapy: a 2-year Swedish national survey of children and adolescents with type 1 diabetes. Pediatr Diabetes 23:1038–1044. https://doi.org/10.1111/pedi.13377CrossRefPubMedPubMedCentral

74.

Giessmann LC, Kann PH (2020) Risk and relevance of insulin pump therapy in the aetiology of ketoacidosis in people with type 1 diabetes. Exp Clin Endocrinol Diabetes 128:745–751. https://doi.org/10.1055/a-0654-5134CrossRefPubMed

75.

Forlenza GP, Lal RA (2022) Current status and emerging options for automated insulin delivery systems. Diabetes Technol Ther 24:362–371. https://doi.org/10.1089/dia.2021.0514CrossRefPubMedPubMedCentral

76.

McVean J, Miller J (2021) MiniMed^TM780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy. Expert Rev Med Devices 18:499–504. https://doi.org/10.1080/17434440.2021.1926984CrossRefPubMed

77.

Crabtree TSJ, Griffin TP, Yap YW et al (2023) Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study. Diabetes Care 46:1831–1838. https://doi.org/10.2337/dc23-0635CrossRefPubMedPubMedCentral

78.

Khan F, Paladino L, Sinert R (2022) The impact of COVID-19 on diabetic ketoacidosis patients. Diabetes Metab Syndr 16:102389. https://doi.org/10.1016/j.dsx.2022.102389CrossRefPubMedPubMedCentral

79.

Misra S, Barron E, Vamos E et al (2021) Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol 9:671–680. https://doi.org/10.1016/S2213-8587(21)00208-4CrossRefPubMedPubMedCentral

80.

Bello-Chavolla OY, Antonio-Villa NE, Fermín-Martínez CA et al (2022) Diabetes-related excess mortality in Mexico: a comparative analysis of national death registries between 2017–2019 and 2020. Diabetes Care 45:2957–2966. https://doi.org/10.2337/dc22-0616CrossRefPubMedPubMedCentral

81.

Lavik AR, Ebekozien O, Noor N et al (2022) Trends in type 1 diabetic ketoacidosis during COVID-19 surges at 7 US centers: highest burden on non-Hispanic Black patients. J Clin Endocrinol Metab 107:1948–1955CrossRefPubMedPubMedCentral

82.

Jin H, Meyer JM, Jeste DV (2004) Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71:195–212. https://doi.org/10.1016/j.schres.2004.03.024CrossRefPubMed

83.

Yuen KCJ, McDaniel PA, Riddle MC (2012) Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol 77:224–232. https://doi.org/10.1111/j.1365-2265.2011.04242.xCrossRef

84.

Shah M, Adel MM, Tahsin B, Guerra Y, Fogelfeld L (2020) Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects. PLoS One 19:e0231190. https://doi.org/10.1371/journal.pone.0231190CrossRef

85.

Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ (2013) Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology 226:1–12. https://doi.org/10.1007/s00213-013-2982-3CrossRefPubMed

86.

Zhang Z, Sharma R, Hamad L, Riebandt G, Attwood K (2023) Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - a comprehensive cancer center experience. Diabetes Res Clin Pract 202:110776. https://doi.org/10.1016/j.diabres.2023.110776CrossRefPubMed

87.

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40:17–65. https://doi.org/10.1210/er.2018-00006CrossRefPubMed

88.

Tittel SR, Laubner K, Schmid SM et al (2021) Immune-checkpoint inhibitor-associated diabetes compared to other diabetes types - a prospective, matched control study. J Diabetes 13:1007–1014. https://doi.org/10.1111/1753-0407.13215CrossRefPubMed

89.

Wu L, Tsang V, Menzies AM et al (2023) Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care 46:1292–1299. https://doi.org/10.2337/dc22-2202CrossRefPubMed

90.

Wolfsdorf JI, Ratner RE (2019) SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care 42:991–993. https://doi.org/10.2337/dci19-0008CrossRefPubMed

91.

Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60:1385–1389. https://doi.org/10.1007/s00125-017-4301-8CrossRefPubMed

92.

Marilly E, Cottin J, Cabrera N et al (2022) SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 65:2000–2010. https://doi.org/10.1007/s00125-022-05773-8CrossRefPubMed

93.

Colacci M, Fralick J, Odutayo A, Fralick M (2022) Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis. Can J Diabetes 46:10-15.e2. https://doi.org/10.1016/j.jcjd.2021.04.006CrossRefPubMed

94.

Bamgboye AO, Oni IO, Collier A (2021) Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol 77:651–657. https://doi.org/10.1007/s00228-020-03051-3CrossRefPubMed

95.

Wu XY, She DM, Wang F et al (2020) Clinical profiles, outcomes and risk factors among type 2 diabetic inpatients with diabetic ketoacidosis and hyperglycemic hyperosmolar state: a hospital-based analysis over a 6-year period. BMC Endocr Disord 20:182. https://doi.org/10.1186/s12902-020-00659-5CrossRefPubMedPubMedCentral

96.

Bonora BM, Avogaro A, Fadini GP (2018) Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab 20:25–33. https://doi.org/10.1111/dom.13012CrossRefPubMed

97.

Blau JE, Tella SH, Taylor SI, Rother KI (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 33. https://doi.org/10.1002/dmrr.2924

98.

Phillips PA, Rolls BJ, Ledingham JGG et al (1984) Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 311:753–759. https://doi.org/10.1056/NEJM198409203111202CrossRefPubMed

99.

Umpierrez GE, Murphy MB, Kitabchi AE (2002) Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. Diabetes Spectr 15:28–36. https://doi.org/10.2337/diaspect.15.1.28CrossRef

100.

Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE (2004) Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 53:2079–2086. https://doi.org/10.2337/diabetes.53.8.2079CrossRefPubMed

101.

Munro JF, Campbell IW, McCuish AC, Duncan LJ (1973) Euglycaemic diabetic ketoacidosis. BMJ 2:578–580. https://doi.org/10.1136/bmj.2.5866.578CrossRefPubMedPubMedCentral

102.

Chow E, Clement S, Garg R (2023) Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care 11:e003666. https://doi.org/10.1136/bmjdrc-2023-003666CrossRefPubMedPubMedCentral

103.

Long B, Lentz S, Koyfman A, Gottlieb M (2021) Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med 44:157–160. https://doi.org/10.1016/j.ajem.2021.02.015CrossRefPubMed

104.

Nasa P, Chaudhary S, Shrivastava PK, Singh A (2021) Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes 12:514–523. https://doi.org/10.4239/wjd.v12.i5.514CrossRefPubMedPubMedCentral

105.

Macfarlane J, Dhatariya K (2019) Incidence of euglycemic diabetic ketoacidosis in adults with type 1 diabetes in the United Kingdom before the widespread use of sodium glucose cotransporter 2 inhibitors. Mayo Clin Proc 94:1909–1910. https://doi.org/10.1016/j.mayocp.2019.06.009CrossRefPubMed

106.

He Z, Lam K, Zhao W et al (2023) SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol 60:401–411. https://doi.org/10.1007/s00592-022-02015-6CrossRefPubMed

107.

Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience. Diabetes Care 45:650–658. https://doi.org/10.2337/dc21-1584CrossRefPubMed

108.

Kilpatrick ES, Butler AE, Ostlundh L, Atkin SL, Sacks DB (2022) Controversies around the measurement of blood ketones to diagnose and manage diabetic ketoacidosis. Diabetes Care 45:267–272. https://doi.org/10.2337/dc21-2279CrossRefPubMedPubMedCentral

109.

Laffel L (1999) Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 15:412–426. https://doi.org/10.1002/(SICI)1520-7560(199911/12)15:6%3c412::AID-DMRR72%3e3.0.CO;2-8CrossRefPubMed

110.

Wolfsdorf JI, Allgrove J, Craig ME et al (2014) ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 15(Suppl 20):154–179. https://doi.org/10.1111/pedi.12165

111.

Huang J, Yeung AM, Bergenstal RM et al (2024) Update on measuring ketones. J Diabetes Sci Technol 18:714–726. https://doi.org/10.1177/19322968231152236CrossRefPubMed

112.

Brooke J, Stiell M, Ojo O (2016) Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review. Int J Environ Res Public Health 13:837. https://doi.org/10.3390/ijerph13090837CrossRefPubMedPubMedCentral

113.

Cao S, Cao S (2023) Diabetic ketoalkalosis: a common yet easily overlooked alkalemic variant of diabetic ketoacidosis associated with mixed acid-base disorders. J Emerg Med 64:282–288. https://doi.org/10.1016/j.jemermed.2022.12.023CrossRefPubMed

114.

Kamel KS, Halperin ML (2015) Acid-base problems in diabetic ketoacidosis. N Engl J Med 372:546–554. https://doi.org/10.1056/NEJMra1207788CrossRefPubMed

115.

Basnet S, Venepalli PK, Andoh J, Verhulst S, Koirala J (2014) Effect of normal saline and half normal saline on serum electrolytes during recovery phase of diabetic ketoacidosis. J Intensive Care Med 29:38–42. https://doi.org/10.1177/0885066612467149CrossRefPubMed

116.

Rao P, Jiang SF, Kipnis P et al (2022) Evaluation of outcomes following hospital-wide implementation of a subcutaneous insulin protocol for diabetic ketoacidosis. JAMA Netw Open 5:e226417. https://doi.org/10.1001/jamanetworkopen.2022.6417CrossRefPubMedPubMedCentral

117.

Mustafa OG, Haq M, Dashora U, Castro E (2023) Management of hyperosmolar hyperglycaemic state (HHS) in adults: an updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 40:e15005. https://doi.org/10.1111/dme.15005CrossRefPubMed

118.

Umpierrez G, Freire AX (2002) Abdominal pain in patients with hyperglycemic crises. J Crit Care 17:63–67. https://doi.org/10.1053/jcrc.2002.33030CrossRefPubMed

119.

Han HJ, Cole AE, Verma A (2023) Euglycemic diabetic ketoacidosis caused by alcoholic pancreatitis and starvation ketosis. J Gen Intern Med 38:1299–1301. https://doi.org/10.1007/s11606-022-07993-5CrossRefPubMedPubMedCentral

120.

Chandrasekara H, Fernando P, Danjuma M, Jayawarna C (2014) Ketoacidosis is not always due to diabetes. BMJ Case Rep 2014:bcr2013203263. https://doi.org/10.1136/bcr-2013-203263

121.

Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE (2004) Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27:1873–1878. https://doi.org/10.2337/diacare.27.8.1873CrossRefPubMed

122.

May ME, Young C, King J (1993) Resource utilization in treatment of diabetic ketoacidosis in adults. Am J Med Sci 306:287–294. https://doi.org/10.1097/00000441-199311000-00003CrossRefPubMed

123.

Javor KA, Kotsanos JG, McDonald RC, Baron AD, Kesterson JG, Tierney WM (1997) Diabetic ketoacidosis charges relative to medical charges of adult patients with type I diabetes. Diabetes Care 20:349–354. https://doi.org/10.2337/diacare.20.3.349CrossRefPubMed

124.

Glaser NS, Ghetti S, Casper TC, Dean JM (2013) Pediatric diabetic ketoacidosis, fluid therapy, and cerebral injury: the design of a factorial randomized controlled trial. Pediatr Diabetes 14:435–446. https://doi.org/10.1111/pedi.12027CrossRefPubMedPubMedCentral

125.

Alghamdi NA, Major P, Chaudhuri D et al (2022) Saline compared to balanced crystalloid in patients with diabetic ketoacidosis: a systematic review and meta-analysis of randomized controlled trials. Crit Care Explor 4:e0613. https://doi.org/10.1097/CCE.0000000000000613CrossRefPubMedPubMedCentral

126.

Self WH, Evans CS, Jenkins CA et al (2020) Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: a subgroup analysis of cluster randomized clinical trials. JAMA Netw Open 3:e2024596. https://doi.org/10.1001/jamanetworkopen.2020.24596CrossRefPubMedPubMedCentral

127.

Catahay JA, Polintan ET, Casimiro M et al (2022) Balanced electrolyte solutions versus isotonic saline in adult patients with diabetic ketoacidosis: a systematic review and meta-analysis. Heart Lung 54:74–79. https://doi.org/10.1016/j.hrtlng.2022.03.014CrossRefPubMed

128.

Jahangir A, Jahangir A, Siddiqui FS et al (2022) Normal saline versus low chloride solutions in treatment of diabetic ketoacidosis: a systematic review of clinical trials. Cureus 14:e21324. https://doi.org/10.7759/cureus.21324CrossRefPubMedPubMedCentral

129.

Bergmann KR, Abuzzahab MJ, Nowak J et al (2021) Resuscitation with Ringer’s lactate compared with normal saline for pediatric diabetic ketoacidosis. Pediatr Emerg Care 37:e236–e242. https://doi.org/10.1097/PEC.0000000000001550CrossRefPubMed

130.

Umpierrez GE, Jones S, Smiley D et al (2009) Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 32:1164–1169. https://doi.org/10.2337/dc09-0169CrossRefPubMedPubMedCentral

131.

Galindo RJ, Pasquel FJ, Fayfman M et al (2020) Clinical characteristics and outcomes of patients with end-stage renal disease hospitalized with diabetes ketoacidosis. BMJ Open Diabetes Res Care 8:e000763. https://doi.org/10.1136/bmjdrc-2019-000763CrossRefPubMedPubMedCentral

132.

Goyal N, Miller JB, Sankey SS, Mossallam U (2010) Utility of initial bolus insulin in the treatment of diabetic ketoacidosis. J Emerg Med 38:422–427. https://doi.org/10.1016/j.jemermed.2007.11.033CrossRefPubMed

133.

Anis TR, Boudreau M, Thornton T (2021) Comparing the efficacy of a nurse-driven and a physician-driven diabetic ketoacidosis (DKA) treatment protocol. Clin Pharmacol 13:197–202. https://doi.org/10.2147/CPAA.S334119CrossRefPubMedPubMedCentral

134.

Singh RK, Perros P, Frier BM (1997) Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively? Diabet Med 14:482–486. https://doi.org/10.1002/(SICI)1096-9136(199706)14:6%3c482::AID-DIA371%3e3.0.CO;2-ACrossRefPubMed

135.

Harrison VS, Rustico S, Palladino AA, Ferrara C, Hawkes CP (2017) Glargine co-administration with intravenous insulin in pediatric diabetic ketoacidosis is safe and facilitates transition to a subcutaneous regimen. Pediatr Diabetes 18:742–748. https://doi.org/10.1111/pedi.12462CrossRefPubMed

136.

Thammakosol K, Sriphrapradang C (2023) Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. Diabetes Obes Metab 25:815–822. https://doi.org/10.1111/dom.14929CrossRefPubMed

137.

Mohamed A, Ploetz J, Hamarshi MS (2021) Evaluation of early administration of insulin glargine in the acute management of diabetic ketoacidosis. Curr Diabetes Rev 17:e030221191986. https://doi.org/10.2174/1573399817666210303095633CrossRefPubMed

138.

Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA (2016) Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev Issue 1, Art no.:CD011281. https://doi.org/10.1002/14651858.CD011281.pub2

139.

Hsia E, Seggelke S, Gibbs J et al (2012) Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 97:3132–3137. https://doi.org/10.1210/jc.2012-1244CrossRefPubMed

140.

Umpierrez GE, Latif K, Stoever J et al (2004) Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med 117:291–296. https://doi.org/10.1016/j.amjmed.2004.05.010CrossRefPubMed

141.

Stuhr K, LeeMaster R, Hickman AW, Reachi B, Pace W, Meek C (2023) Subcutaneous insulin versus traditional intravenous insulin infusion in treatment of mild to moderate diabetic ketoacidosis. J Emerg Med 65:e221–e228. https://doi.org/10.1016/j.jemermed.2023.06.004CrossRefPubMed

142.

Karoli R, Fatima J, Salman T, Sandhu S, Shankar R (2011) Managing diabetic ketoacidosis in non-intensive care unit setting: role of insulin analogs. Indian J Pharmacol 43:398–401. https://doi.org/10.4103/0253-7613.83109CrossRefPubMedPubMedCentral

143.

Kitabchi AE, Ayyagari V, Guerra SM (1976) The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. Ann Intern Med 84:633–638. https://doi.org/10.7326/0003-4819-84-6-633CrossRefPubMed

144.

ElSayed NA, Aleppo G, Aroda VR et al (2024) 16. Diabetes care in the hospital: Standards of Care in Diabetes—2024. Diabetes Care 47(Suppl 1):S295–S306. https://doi.org/10.2337/dc24-S016

145.

Arora S, Cheng D, Wyler B, Menchine M (2012) Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med 30:481–484. https://doi.org/10.1016/j.ajem.2011.01.002

146.

Harris AN, Grimm PR, Lee HW et al (2018) Mechanism of hyperkalemia-induced metabolic acidosis. J Am Soc Nephrol 29:1411–1425. https://doi.org/10.1681/ASN.2017111163CrossRefPubMedPubMedCentral

147.

Murthy K, Harrington JT, Siegel RD (2005) Profound hypokalemia in diabetic ketoacidosis: a therapeutic challenge. Endocr Pract 11:331–334. https://doi.org/10.4158/EP.11.5.331CrossRefPubMed

148.

Cieluch A, Uruska A, Falkowski B et al (2018) Nonadherence to potassium replacement protocol leads to prolonged management of diabetic ketoacidosis. Pol Arch Intern Med 128:416–420. https://doi.org/10.20452/pamw.4293CrossRefPubMed

149.

Chua HR, Schneider A, Bellomo R (2011) Bicarbonate in diabetic ketoacidosis - a systematic review. Ann Intensive Care 1:23. https://doi.org/10.1186/2110-5820-1-23CrossRefPubMedPubMedCentral

150.

Glaser N, Barnett P, McCaslin I et al (2001) Risk factors for cerebral edema in children with diabetic ketoacidosis. N Engl J Med 344:264–269. https://doi.org/10.1056/NEJM200101253440404CrossRefPubMed

151.

Ditzel J, Lervang HH (2010) Disturbance of inorganic phosphate metabolism in diabetes mellitus: clinical manifestations of phosphorus-depletion syndrome during recovery from diabetic ketoacidosis. Diabetes Metab Syndr Obes 3:319–324. https://doi.org/10.2147/DMSO.S13476CrossRefPubMedPubMedCentral

152.

Fisher JN, Kitabchi AE (1983) A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 57:177–180. https://doi.org/10.1210/jcem-57-1-177CrossRefPubMed

153.

Everett E, Mathioudakis NN (2019) Association of socioeconomic status and DKA readmission in adults with type 1 diabetes: analysis of the US National Readmission Database. BMJ Open Diabetes Res Care 7:e000621. https://doi.org/10.1136/bmjdrc-2018-000621CrossRefPubMedPubMedCentral

154.

Gosmanov AR, Gosmanova EO, Kitabchi AE (2000) Hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. In: Feingold KR, Anawalt B, Blackman MR et al (eds). Endotext. MDText.com, Inc., South Dartmouth, MA. Available from www.ncbi.nlm.nih.gov/books/NBK279052/. Accessed: 28 September 2023

155.

Harris MA, Wagner DV, Heywood M, Hoehn D, Bahia H, Spiro K (2014) Youth repeatedly hospitalized for DKA: proof of concept for novel interventions in children’s healthcare (NICH). Diabetes Care 37:e125–e126. https://doi.org/10.2337/dc13-2232CrossRefPubMed

156.

Ehrmann D, Kulzer B, Roos T, Haak T, Al-Khatib M, Hermanns N (2020) Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol 8:436–446. https://doi.org/10.1016/S2213-8587(20)30042-5CrossRefPubMed

157.

Tekin Z, Saygili M (2022) The association between Medicaid expansion and diabetic ketoacidosis hospitalizations. Cureus 14:e30631. https://doi.org/10.7759/cureus.30631CrossRefPubMedPubMedCentral

158.

Elliott J, Jacques RM, Kruger J et al (2014) Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with type 1 diabetes. Diabet Med 31:847–853. https://doi.org/10.1111/dme.12441CrossRefPubMedPubMedCentral

159.

Lee JH, Orr-Walker BJ (2020) Diabetic ketoacidosis admissions at Middlemore Hospital: observational study of cause and patient demographics. N Z Med J 133:34–40PubMed

160.

Diguisto C, Strachan MWJ, Churchill D, Ayman G, Knight M (2022) A study of diabetic ketoacidosis in the pregnant population in the United Kingdom: investigating the incidence, aetiology, management and outcomes. Diabet Med 39:e14743. https://doi.org/10.1111/dme.14743CrossRefPubMed

161.

Albanese-O’Neill A, Wu M, Miller KM, Jacobsen L, Haller MJ (2017) Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care 40:e38–e39 https://doi.org/10.2337/dc16-2620

162.

Holt RIG, DeVries JH, Hess-Fischl A et al The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2021;64:2609–2652. https://doi.org/10.1007/s00125-021-05568-3

163.

Riveline JP, Roussel R, Vicaut E et al (2022) Reduced rate of acute diabetes events with flash glucose monitoring is sustained for 2 years after initiation: extended outcomes from the RELIEF study. Diabetes Technol Ther 24:611–618. https://doi.org/10.1089/dia.2022.0085CrossRefPubMed

164.

Roussel R, Riveline JP, Vicaut E et al (2021) Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care 44:1368–1376. https://doi.org/10.2337/dc20-1690CrossRefPubMedPubMedCentral

165.

Spanakis EK, Cook CB, Kulasa K et al (2023) A consensus statement for continuous glucose monitoring metrics for inpatient clinical trials. J Diabetes Sci Technol 17:1527–1552. https://doi.org/10.1177/19322968231191104CrossRefPubMedPubMedCentral

166.

Galm BP, Bagshaw SM, Senior PA (2019) Acute management of diabetic ketoacidosis in adults at 3 teaching hospitals in Canada: a multicentre, retrospective cohort study. Can J Diabetes 43:309-315.e2. https://doi.org/10.1016/j.jcjd.2018.11.003CrossRefPubMed

167.

Tian T, Aaron RE, Seley JJ et al (2024) Use of continuous glucose monitors upon hospital discharge of people with diabetes: promise, barriers, and opportunity. J Diabetes Sci Technol 18:207–214. https://doi.org/10.1177/19322968231200847CrossRefPubMed

168.

Nguyen KT, Xu NY, Zhang JY et al (2022) Continuous ketone monitoring consensus report 2021. J Diabetes Sci Technol 16:689–715. https://doi.org/10.1177/19322968211042656CrossRefPubMed

169.

Hamblin PS, Abdul-Wahab AL, Xu SFB, Steele CE, Vogrin S (2022) Diabetic ketoacidosis: a canary in the mine for mental health disorders? Intern Med J 52:1002–1008. https://doi.org/10.1111/imj.15214CrossRefPubMed

170.

Gaffney A, Himmelstein DU, Woolhandler S (2022) Prevalence and correlates of patient rationing of insulin in the United States: a national survey. Ann Intern Med 175:1623–1626. https://doi.org/10.7326/M22-2477CrossRefPubMed

171.

Fang M, Selvin E (2023) Cost-related insulin rationing in US adults younger than 65 years with diabetes. JAMA 329:1700–1702. https://doi.org/10.1001/jama.2023.5747CrossRefPubMedPubMedCentral

172.

Nip ASY, Lodish M (2021) Trend of diabetes-related hospital admissions during the transition period from adolescence to adulthood in the state of California. Diabetes Care 44:2723–2728. https://doi.org/10.2337/dc21-0555CrossRefPubMed

173.

Rewers A, Kuppermann N, Stoner MJ et al (2021) Effects of fluid rehydration strategy on correction of acidosis and electrolyte abnormalities in children with diabetic ketoacidosis. Diabetes Care 44:2061–2068. https://doi.org/10.2337/dc20-3113CrossRefPubMedPubMedCentral

174.

Mahler SA, Conrad SA, Wang H, Arnold TC (2011) Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med 29:670–674. https://doi.org/10.1016/j.ajem.2010.02.004CrossRefPubMed

175.

Wei WT, Lin SM, Hsu JY et al (2022) Association between hyperosmolar hyperglycemic state and venous thromboembolism in diabetes patients: a nationwide analysis in Taiwan. J Pers Med 12:302. https://doi.org/10.3390/jpm12020302CrossRefPubMedPubMedCentral

176.

Pillai S, Davies G, Lawrence M et al (2021) The effect of diabetic ketoacidosis (DKA) and its treatment on clot microstructure: are they thrombogenic? Clin Hemorheol Microcirc 77:183–194CrossRefPubMed

177.

Siwakoti K, Giri S, Kadaria D (2017) Cerebral edema among adults with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome: incidence, characteristics, and outcomes. J Diabetes 9:208–209. https://doi.org/10.1111/1753-0407.12448CrossRefPubMed

178.

Kusumoto K, Koriyama N, Kojima N, Ikeda M, Nishio Y (2020) Central pontine myelinolysis during treatment of hyperglycemic hyperosmolar syndrome: a case report. Clin Diabetes Endocrinol 6:23. https://doi.org/10.1186/s40842-020-00111-6CrossRefPubMedPubMedCentral

179.

Orban JC, Maizière EM, Ghaddab A, Van Obberghen E, Ichai C (2014) Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis. PLoS One 9:e110925. https://doi.org/10.1371/journal.pone.0110925CrossRefPubMedPubMedCentral

180.

Chen IW, Lin CW (2018) Improvement in renal prognosis with prompt hemodialysis in hyperosmolar hyperglycemic state-related rhabdomyolysis: a case report. Medicine 97:e13647. https://doi.org/10.1097/MD.0000000000013647CrossRefPubMedPubMedCentral

181.

Schwarzfuchs D, Rabaev E, Sagy I et al (2020) Clinical and epidemiological characteristics of diabetic ketoacidosis in older adults. J Am Geriatr Soc 68:1256–1261. https://doi.org/10.1111/jgs.16376CrossRefPubMed

182.

Dhatariya K (2022) Initiation and continuation of sodium-glucose cotransporter 2 inhibitors in hospital inpatients: ready for prime time? Diabetes Care 45:2806–2807. https://doi.org/10.2337/dci22-0039CrossRefPubMed

183.

Galindo RJ, Pasquel FJ, Vellanki P et al (2021) Biochemical parameters of diabetes ketoacidosis in patients with end-stage kidney disease and preserved renal function. J Clin Endocrinol Metab 106:e2673–e2679. https://doi.org/10.1210/clinem/dgab126CrossRefPubMedPubMedCentral

184.

Dhanasekaran M, Mohan S, Erickson D et al (2022) Diabetic ketoacidosis in pregnancy: clinical risk factors, presentation, and outcomes. J Clin Endocrinol Metab 107:3137–3143. https://doi.org/10.1210/clinem/dgac464CrossRefPubMedPubMedCentral

185.

Birkebaek NH, Kamrath C, Grimsmann JM et al (2022) Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol 10:786–794. https://doi.org/10.1016/S2213-8587(22)00246-7CrossRefPubMedPubMedCentral

ERS Congress 2024

Springer Medicine

Hyperglycaemic crises in adults with diabetes: a consensus report

Abstract

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2024

Capillary contact points determine beta cell polarity, control secretion and are disrupted in the db/db mouse model of diabetes

Identification and validation of gestational diabetes subgroups by data-driven cluster analysis

Is strength training more effective than aerobic exercise for improving glycaemic control and body composition in people with normal-weight type 2 diabetes?

Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study

Role of weight loss-induced prediabetes remission in the prevention of type 2 diabetes: time to improve diabetes prevention

Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials

At a glance: The STEP trials